Book chapters will be unavailable on Saturday 24th August between 8am-12pm BST. This is for essential maintenance which will provide improved performance going forwards. Please accept our apologies for any inconvenience caused.
To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure email@example.com
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Therapeutic application of the physiologic process of fibrinolysis (thrombolysis) was first attempted in the late 1950s in individuals with various thrombotic lesions, comprising peripheral venous, arterial, central nervous system (CNS) and coronary involvement . Over time and after rigorous clinical study, intravascular thrombolysis has come to occupy a critical role in the management of thrombotic disease in adults, with clear, approved indications for acute myocardial infarction, stroke and massive pulmonary embolism (PE). Its utility has also been investigated recently via controlled clinical trials in adults with occlusive lower extremity deep vein thrombosis (DVT), with promising results ; current guidelines also suggest its use in selected patients with this common condition .
For many reasons, however, including the lower incidence of thrombotic disease, consequent difficulty in completing high-quality clinical trials and heightened concerns for bleeding risks in young infants and children, the indications, dosing regimens and safety profiles for thrombolysis in pediatric patients are not as well established. Overall, the quality of evidence supporting the clinical management of pediatric patients via thrombolysis remains low given that a large proportion of the existing literature consists of individual case reports and small case series. Most series have reported on clinically heterogeneous groups of patients, with varied sites of vascular involvement using a variety of thrombolytic dosing regimens and modalities. Several comprehensive literature reviews have been published compiling available safety, efficacy and dosing data from several hundred infants and children [4–6]. Other recent review articles [7–9] summarize experience, expert opinion and important clinical management principles, while practice guidelines [10,11] are available to provide formal recommendations based on existing evidence.